STOCK TITAN

Alnylam Pharmaceuticals Inc - ALNY STOCK NEWS

Welcome to our dedicated news page for Alnylam Pharmaceuticals (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alnylam Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alnylam Pharmaceuticals's position in the market.

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) presents positive initial Phase 1 results for ALN-TTRsc04 and ALN-KHK, with rapid knockdown and robust target engagement. The company anticipates IND applications for nine or more programs by the end of 2025, showcasing its R&D progress and platform innovation, as well as its product and pipeline goals for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
none
-
News
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) to Webcast Virtual R&D Day Event on December 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
conferences
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has been ranked as the #1 Top Place to Work in the 'Largest Employer' category by The Boston Globe for the third consecutive year. This recognition is based on an anonymous survey completed by 137,000 employees across 347 different companies in Massachusetts, focusing on workplace environment, company direction, execution, connection, management, work, pay and benefits, and engagement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
none
Rhea-AI Summary
ALNY - Alnylam Pharmaceuticals, Inc. - announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension treatment. The study achieved a 16.7 mmHg placebo-adjusted reduction in 24-hour mean systolic blood pressure at 3 months. Zilebesiran also demonstrated consistent and sustained reductions in systolic blood pressure up to 6 months, supporting quarterly or biannual dosing. The study showed encouraging safety and tolerability in adult patients with mild-to-moderate hypertension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. will present company overviews at three upcoming healthcare conferences in November 2023, providing live audio webcasts and replays on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
conferences
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. reported Q3 2023 global net product revenues of $313 million, a 35% YoY growth. They received a Complete Response Letter from the FDA for a supplemental new drug application for Patisiran. The company remains on track to report topline results from the HELIOS-B Phase 3 study in early 2024. They also reported positive topline results from the KARDIA-1 Phase 2 study of Zilebesiran. Alnylam updated their 2023 revenue guidance and reiterated their guidance for combined net product revenues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
earnings
Rhea-AI Summary
Alnylam Pharmaceuticals has been ranked third in Science magazine’s Top Employer Survey for 2023, marking the fifth year the company has been featured in the top three. The survey included over 6,800 professionals in the biotechnology and biopharmaceutical industries, who rated companies based on 24 characteristics. Alnylam's top attributes included treating employees with respect, social responsibility, and work culture values aligned with personal values.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
none
-
Rhea-AI Summary
Alnylam Pharmaceuticals announced results from the APOLLO-B Phase 3 study of patisiran in patients with ATTR amyloidosis. The study showed that patisiran preserved functional capacity and health status compared to placebo at 12 months. Patisiran also demonstrated favorable effects on cardiac biomarkers and measures of cardiac structure and function. The results support the potential of RNAi therapeutics in treating ATTR amyloidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
clinical trial
-
Rhea-AI Summary
Alnylam Pharmaceuticals announces positive interim results for ALN-APP in the treatment of Alzheimer’s disease and cerebral amyloid angiopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
clinical trial
Rhea-AI Summary
Alnylam Pharmaceuticals to report Q3 2023 financial results on November 2nd
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
conferences earnings
Alnylam Pharmaceuticals Inc

Nasdaq:ALNY

ALNY Rankings

ALNY Stock Data

19.44B
125.42M
0.4%
95.08%
2.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About ALNY

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.